Development of Products Based on Secretom From Stem Cell Conditioned Medium for Melasma Therapy

Inclusion Criteria: * Women diagnosed with melasma. * Women without melasma and have areas of skin that are clinically free of lesions for SP control. * 30-60 years old. * Fitzpatrick skin type IV-V. * Willing to be a research subject by signing a research consent form (Informed Consent). Exclusion Criteria: * Pregnant and breastfeeding women. * Currently using hormonal contraception or have ever used contraception hormones in the last 6 months. * Using topical therapy for melasma, for example corticosteroids, tretinoin, hydroquinone, and other therapies that whiten or brighten the skin in the last 2 weeks. * Using topical triple combination cream therapy for at least 3 months and did not show significant improvement * Using systemic therapy for melasma, for example antioxidants or tranexamic acid in the last 4 weeks. * History of superficial peeling therapy in the last 4 weeks. * History of deep peeling therapy, laser or mechanical abrasion in the last 6 months. * Using drugs that are photosensitizers such as tetracycline, phenytoin, carbamazepine, spironolactone. * History of blood clotting disorders or on blood thinning therapy. * Allergy to tranexamic acid. * Have other skin complaints that may interfere with the evaluation of melasma, for example post-inflammatory hyperpigmentation, Hori's nevus, Ota's nevus, pigmented contact dermatitis, and other pigmentation disorders * Difficulty complying with treatment.